Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis
The purpose of this study is to determine whether BMS-986036 is effective in the treatment of subjects with Non-alcoholic Steatohepatitis (NASH).
Age
21 - 75 years
Sex
ALL
Healthy Volunteers
No
Inland Empire Liver Foundation
Rialto, California, United States
University Of California, San Diego
San Diego, California, United States
Indiana University Health - University Hospital
Indianapolis, Indiana, United States
Saint Louis University
St Louis, Missouri, United States
Unc Hospitals And Clinics
Chapel Hill, North Carolina, United States
Carolinas Healthcare System
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States
Upmc Center For Liver Diseases
Pittsburgh, Pennsylvania, United States
Gastro One
Germantown, Tennessee, United States
Start Date
May 8, 2015
Primary Completion Date
January 18, 2017
Completion Date
June 19, 2017
Last Updated
February 26, 2021
184
ACTUAL participants
BMS-986036
DRUG
BMS-986036
DRUG
Placebo
DRUG
Lead Sponsor
Bristol-Myers Squibb
NCT06819917
NCT06661655
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions